Drug intelligence / Profile preview

Heweiyangxue

Development stage: Phase 2
Lead developer: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Administration: Oral

Overview

Heweiyangxue is a Traditional Chinese Medicine (TCM) formula developed by the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with the Shanghai University of Traditional Chinese Medicine. The formula is designed to address chemotherapy-related gastrointestinal reactions, such as nausea, vomiting, and anorexia, in patients with non-small cell lung cancer (NSCLC). Based on TCM principles, Heweiyangxue aims to benefit qi, nourish blood, and tonify the stomach to mitigate the toxic side effects of chemotherapy. It is currently being evaluated in randomized controlled trials to establish its clinical efficacy and safety as a supportive care intervention for cancer patients undergoing chemotherapy.

Other names: Heweiyangxue decoctionHeweiyangxue formulaHeweiyangxue recipe

Beyond the preview

Go deeper on Heweiyangxue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heweiyangxue.